Hongmei He, Wenhui Kou, Huanhuan Wang, Shujing Ma, Haiyan Zhang, Yuan Zou, Xiuzhen Zhai, Qian Xue*
Department of Neurology, the First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, Hebei Province, PR China
Introduction: To explore the clinical efficacy and safety of ischemic preconditioning therapy assisted with ultra-early recombinant tissue plasminogen activator (rt-PA) thrombosis in the treatment of acute cerebral infarction(ACI) patients.
Materials and methods: 126 ACI patients admitted to our hospital from January 2021 to January 2022 were enrolled prospectively and divided into two groups using random number table method: the control group (63 cases) who were treated with ultra-early RT-PA thrombosis and the experimental group (63 cases) who were treated with ischemic preconditioning therapy on the basis of control group. 2 groups were compared in terms of the overall response rate, National Institutes of Health Stroke Scale (NIHSS) score, modified Rankin Scale (MRS) score, incidence of adverse reactions and follow-up Glasgow Outcome Scale (GOS) score before and after treatment.
Results: The overall response rate of the experimental group was significantly higher than that of the control group (P<0.05). The NIHSS score and Mrs score in the experimental group after treatment were significantly lower than those in the control group and before treatment (P<0.05). There was no significant difference between 2 groups in the incidence of adverse reactions (P>0.05). The good outcome rate based on follow-up GOS score in the experimental group was significantly higher than that in the control group (P<0.05).
Conclusion: Ischemic preconditioning therapy assisted with ultra-early RT-PA thrombosis can effectively promote the effect of disease control, protect neurological function and improve clinical outcome in ACI patients and have satisfactory safety.
Ischemic preconditioning, recombinant tissue plasminogen activator, thrombolysis, acute cerebral infarction.
10.19193/0393-6384_2022_5_527